Cargando…

Inhibiting autophagy increases epirubicin's cytotoxicity in breast cancer cells

Chemotherapy, radiotherapy, and endocrinotherapy are documented to induce autophagy among breast cancer cells, but the role of autophagy in this disease has been attributed as cytoprotective as well as tumor‐suppressing. Thus we studied MDA‐MB‐231 and SK‐BR‐3 breast cancer cell lines treated with ep...

Descripción completa

Detalles Bibliográficos
Autores principales:	Guo, Wei, Wang, Yu, Wang, Zhu, Wang, Yan‐Ping, Zheng, Hong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2016
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5132286/ https://www.ncbi.nlm.nih.gov/pubmed/27560771 http://dx.doi.org/10.1111/cas.13059

Ejemplares similares

Ambra1 modulates the sensitivity of breast cancer cells to epirubicin by regulating autophagy via ATG12
por: Sun, Wei‐Liang, et al.
Publicado: (2018)

Ulinastatin Reduces the Resistance of Liver Cancer Cells to Epirubicin by Inhibiting Autophagy
por: Song, Bin, et al.
Publicado: (2015)

Epirubicin sequential natural killer cells enhanced the cytotoxicity to breast cancer cells in vitro
por: Song, Yanqiu, et al.
Publicado: (2015)

Epirubicin-induced Kounis syndrome
por: Liang, Hui-zhu, et al.
Publicado: (2021)

Nanostructured Dihydroartemisinin Plus Epirubicin Liposomes Enhance Treatment Efficacy of Breast Cancer by Inducing Autophagy and Apoptosis
por: Hu, Ying-Jie, et al.
Publicado: (2018)

Inhibition of autophagy enhances the cytotoxic effect of PA-MSHA in breast cancer
por: Xu, Wen-Huan, et al.
Publicado: (2014)

Epirubicin
por: Cornish, J., et al.
Publicado: (1988)

OTUB1 inhibits the ubiquitination and degradation of FOXM1 in breast cancer and epirubicin resistance
por: Karunarathna, U, et al.
Publicado: (2016)

Melatonin increases the chemosensitivity of diffuse large B-cell lymphoma cells to epirubicin by inhibiting P-glycoprotein expression via the NF-κB pathway
por: Liu, Kaili, et al.
Publicado: (2020)

Progesterone Increases Apoptosis and Inversely Decreases Autophagy in Human Hepatoma HA22T/VGH Cells Treated with Epirubicin
por: Chang, Wen-Tsan, et al.
Publicado: (2014)

Preexposure of MCF-7 breast cancer cell line to dexamethasone alters the cytotoxic effect of paclitaxel but not 5-fluorouracil or epirubicin chemotherapy
por: Buxant, Frederic, et al.
Publicado: (2017)

Chloroquine enhances the cytotoxicity of topotecan by inhibiting autophagy in lung cancer cells
por: Wang, Yao, et al.
Publicado: (2011)

Oral vinorelbine versus intravenous vinorelbine, in combination with epirubicin as first-line chemotherapy in Chinese patients with metastatic breast cancer
por: Huang, Liang, et al.
Publicado: (2019)

The use of functional epirubicin liposomes to induce programmed death in refractory breast cancer
por: Liu, Lei, et al.
Publicado: (2017)

A Potential Daidzein Derivative Enhances Cytotoxicity of Epirubicin on Human Colon Adenocarcinoma Caco-2 Cells
por: Lo, Yu-Li
Publicado: (2012)

Phase II multicentre randomised study of docetaxel plus epirubicin vs 5-fluorouracil plus epirubicin and cyclophosphamide in metastatic breast cancer
por: Bonneterre, J, et al.
Publicado: (2004)

Chloroquine increases the anti-cancer activity of epirubicin in A549 lung cancer cells
por: Liang, Ai-Ling, et al.
Publicado: (2020)

Incidence of chemotherapy-induced amenorrhea associated with epirubicin, docetaxel and navelbine in younger breast cancer patients
por: Zhou, Wen-Bin, et al.
Publicado: (2010)

Weekly epirubicin for breast cancer with liver metastases and abnormal liver biochemistry.
por: Twelves, C. J., et al.
Publicado: (1989)

A phase II trial of paclitaxel and epirubicin in advanced breast cancer
por: Rischin, D, et al.
Publicado: (2000)

A pilot study of quinidine and epirubicin in the treatment of advanced breast cancer.
por: Jones, R. D., et al.
Publicado: (1990)

Differential immunomodulatory effects of epirubicin/cyclophosphamide and docetaxel in breast cancer patients
por: Wimmer, Kerstin, et al.
Publicado: (2023)

Ursolic Acid Enhances the Sensitivity of MCF-7 and MDA-MB-231 Cells to Epirubicin by Modulating the Autophagy Pathway
por: Wang, Zhennan, et al.
Publicado: (2022)

Clonal evolution in primary breast cancers under sequential epirubicin and docetaxel monotherapy
por: Venizelos, Andreas, et al.
Publicado: (2022)

Inhibition of KRAS-dependent lung cancer cell growth by deltarasin: blockage of autophagy increases its cytotoxicity
por: Leung, Elaine Lai Han, et al.
Publicado: (2018)

Knockdown of TRPM8 Suppresses Cancer Malignancy and Enhances Epirubicin-induced Apoptosis in Human Osteosarcoma Cells
por: Wang, Yongzhi, et al.
Publicado: (2013)

ABTB2 Regulatory Variant as Predictor of Epirubicin-Based Neoadjuvant Chemotherapy in Luminal A Breast Cancer
por: Gong, Yajie, et al.
Publicado: (2020)

Inhibition of 6-Phosphogluconate Dehydrogenase Reverses Epirubicin Resistance Through Metabolic Reprograming in Triple-Negative Breast Cancer Cells
por: Xu, Jiali, et al.
Publicado: (2023)

MEDAG enhances breast cancer progression and reduces epirubicin sensitivity through the AKT/AMPK/mTOR pathway
por: Li, Zhiyu, et al.
Publicado: (2021)

High expression of UBD correlates with epirubicin resistance and indicates poor prognosis in triple-negative breast cancer
por: Han, Tao, et al.
Publicado: (2015)

Multicenter randomized phase III trial of Epirubicin plus Paclitaxel vs Epirubicin followed by Paclitaxel in metastatic breast cancer patients: focus on cardiac safety
por: Baldini, E, et al.
Publicado: (2004)

The Efficacy and Toxicity of Neoadjuvant Chemotherapy Regimens of Epirubicin Plus Cyclophosphamide Followed by Docetaxel or Paclitaxel in Female Breast Cancer Patients
por: Wu, Xian, et al.
Publicado: (2021)

High Expression of Pyruvate Kinase M2 is Associated with Chemosensitivity to Epirubicin and 5-Fluorouracil in Breast Cancer
por: Lin, Yang, et al.
Publicado: (2015)

Neoadjuvant rh-endostatin, docetaxel and epirubicin for breast cancer: efficacy and safety in a prospective, randomized, phase II study
por: Chen, Jianghao, et al.
Publicado: (2013)

Cyclophosphamide and epirubicin-induced diabetes mellitus in breast cancer: A rare occurrence
por: Sharma, Pramod Kumar, et al.
Publicado: (2016)

Novel Long Noncoding RNA 005620 Induces Epirubicin Resistance in Triple-Negative Breast Cancer by Regulating ITGB1 Expression
por: Wang, Fengliang, et al.
Publicado: (2021)

Weekly epirubicin plus docetaxel as first-line treatment in metastatic breast cancer
por: Gamucci, T, et al.
Publicado: (2007)

The implication from RAS/RAF/ERK signaling pathway increased activation in epirubicin treated triple negative breast cancer
por: Huang, Jianbo, et al.
Publicado: (2017)

Melatonin protects against Epirubicin-induced ovarian damage
por: WANG, Naiqiang, et al.
Publicado: (2019)

The Chk1 inhibitor MK-8776 increases the radiosensitivity of human triple-negative breast cancer by inhibiting autophagy
por: Zhou, Zhi-rui, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_ianel6g5c0jrvgmutv8f5qe8i3